New Pfizer Data Presented On CP-751,871 Across Non-small Cell Lung Cancer And Ewing's Sarcoma

Pfizer announced results from several clinical trials further describing the activity of its investigational compound CP-751,871 in non-small cell lung cancer (NSCLC) and Ewing's Sarcoma, both diseases with high unmet medical need. The three oral presentations and one poster discussion underscore that the insulin-like growth factor receptor (IGF-1R) is increasingly recognized by the medical community as a relevant target for investigation in cancer research. The results were presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL. Updated Response Data from the 1002 NSCLC Trial Updated study results from a Phase II, randomized, non-comparative study showed 54 percent of patients with Sta...